Future Science Group
Browse
1/1
4 files

Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. Supplementary Table 1 and figures 1-3

figure
posted on 2022-07-27, 08:30 authored by Elena Sakanjanb, Denis Logunovc, Inna Dolzhikovac, Irina Efimovab, Nataliya Zubkovab, Alina Sokolovab, Anton Perevozchikovb, Natalia Seleznevab, Tatyana Vyaznikovab, Olga Belyakovab, Aleksandr Ivanovb, Ekaterina Orlovab, Alevtina Nikolaevab, Tatiana Smolyanovaa, Mikhail Razumikhina

Supplementary table 1.   Biochemical and hematological parameters of laboratory animals in 14 days after infusion with COVID-globulin.


Supplementary figure 1.  Histopathological examination of the organs of rats treated with COVID-globulin showed no signs of necrosis, inflammation, atypia, or any significant pathological changes.


Supplementary figure 2.  Two out of the four animals in groups 1 and 2 (COVID-globulin administered 24 h before and 2 h after infection) showed significantly lower levels of lung damage.


Supplementary figure 3.  Histological examination of lung tissues.

History